There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
Show figures in :Show figures in :
Data is unavailable
Data is unavailable
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net worth | 2172.72 | 1849.28 | 1666.30 | 1501.61 | 1245.06 | 1032.81 | 945.50 | 787.85 | 595.52 | 507.35 |
| Fixed assets | 1134.99 | 1193.83 | 1305.06 | 1368.81 | 447.26 | 413.02 | 208.66 | 207.52 | 152.43 | 165.64 |
| Debt | - | 83.33 | 236.67 | 345.65 | 0.12 | - | - | - | - | - |
View detailed balance sheet
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 568.89 | 535.33 | 456.03 | 446.69 | 398.15 | 283.89 | 218.54 | 197.07 | 171.31 | 158.54 |
| Investing | -303.16 | -24.27 | -287.31 | -449.25 | -212.02 | -26.11 | -99.74 | -172.28 | -137.11 | -163.49 |
| Financing | -334.03 | -413.86 | -283.18 | 136.45 | -138.56 | -190.45 | -55.26 | 12.51 | -32.26 | 0.36 |
The company offers 5,000+ diagnostic tests and panels, including specialised and genomic testing across key laboratory disciplines . Its portfolio includes Genevolve (genomics), L-CoRD (reproductive diagnostics) and L-ACE (autoimmune disorders), along with AI-enabled diagnostics .
Dr. Lal PathLabs has a Pan-India presence with 298 labs, 6,607 patient service centres and 12,365 pick-up points, and also operates in Nepal and Bangladesh through subsidiaries and labs . International operations currently account for less than 2% of revenue .
In FY25, revenue contribution was 74% from B2C and 26% from B2B . International revenue was less than 2%, with the rest from India .
